Lantheus (NASDAQ:LNTH) Issues FY 2026 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 5.000-5.250 for the period, compared to the consensus earnings per share estimate of 5.160. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LNTH shares. Mizuho raised their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Truist Financial raised their price objective on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Citizens Jmp increased their target price on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a report on Tuesday. Finally, Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.83.

Lantheus Trading Up 2.9%

Lantheus stock opened at $75.72 on Thursday. The stock has a 50-day moving average price of $67.76 and a 200 day moving average price of $59.90. Lantheus has a 52 week low of $47.25 and a 52 week high of $111.29. The stock has a market cap of $5.02 billion, a PE ratio of 31.82 and a beta of -0.08. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its stake in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the period. Vident Advisory LLC raised its position in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after purchasing an additional 230 shares during the period. Parallel Advisors LLC boosted its position in shares of Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the period. Orion Porfolio Solutions LLC grew its stake in shares of Lantheus by 3.9% in the second quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider’s stock valued at $819,000 after buying an additional 377 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.